Onychomycosis Treatment Market, By Treatment Type, By Type, By Geography

Description

Onychomycosis Treatment Market is estimated to be valued at USD 3,755 Mn in 2026 and is expected to reach USD 5,497 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.6% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 3,755 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	5.60%	2033 Value Projection:	USD 5,497 Mn

Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit. For treatment, drugs remain the first-line treatment choice owing to a consistently high success rate. A newer generation of oral antifungal agents (itraconazole and terbinafine) has replaced older therapies in the treatment of onychomycosis.

Market Dynamics

Risk of onychomycosis in diabetic patient or increase in prevalence of diabetes, growing geriatric population, increase in demand for safe and effective treatment, rise in focus on the development of novel onychomycosis treatments, and growing awareness among people about potential threats of onychomycosis and available treatments are major factors expected to drive growth of the global onychomycosis treatment market over the forecast period.

For instance, in April 2021, Alembic Pharmaceuticals Limited (Alembic) announced that its joint venture Aleor Dermaceuticals Limited (Aleor) received tentative approval from the U.S. Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for Efinaconazole Topical Solution for the treatment of onychomycosis in the toenail.

Moreover, in October 2020, Mundipharma launched the latest addition to its BETADINE range of infectious disease therapies. This BETADINE EMTRIX fungal nail solutions effectively treats the onychomycosis and improves the nail appearance after regular application.

Key features of the study

This report provides in-depth analysis of the global onychomycosis treatment market, and provides market size (USD Mn) and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global onychomycosis treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Lumenis Ltd., Cipla Ltd., Bayer AG, Johnson & Johnson, Moberg Pharma AB, Pfizer Inc., Novartis, Galderma SA, Dr. Reddys Laboratories Ltd., Medimetriks Pharmaceuticals Inc., and Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.), among others.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global onychomycosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global onychomycosis treatment market.

Onychomycosis Treatment Market Segmentation

By Treatment Type Insights (Revenue, USD Mn, 2020 - 2033)
- Drugs
- Laser Therapy
- Photodynamic Therapy
By Type Insights (Revenue, USD Mn, 2020 - 2033)
- Distal Subungual Onychomycosis
- White Superficial Onychomycosis
- Proximal Subungual Onychomycosis
- Other Types
By Region Insights (Revenue, USD Mn, 2020 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
Key Players in the Onychomycosis Treatment Market
- Lumenis Ltd.
- Cipla Ltd.
- Bayer AG
- Johnson & Johnson
- Moberg Pharma AB
- Pfizer Inc.
- Novartis
- Galderma SA
- Reddys Laboratories Ltd.
- Medimetriks Pharmaceuticals Inc.
- Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.)
- Others.

Product Code: CMI5423

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Treatment Type
- Market Snapshot, By Type
- Market Snapshot, By Geography
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Increasing prevalence of onychomycosis around the world
- Availability of alternative treatment options
- Rise in demand for safe/effective onychomycosis treatment
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Onychomycosis Treatment Market, By Treatment Type, 2020-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2020 - 2033
- Segment Trends
Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
Laser Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
Photodynamic Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

5. Global Onychomycosis Treatment Market By Type, 2020-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2020 - 2033
- Segment Trends
Distal Subungual Onychomycosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
White Superficial Onychomycosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
Proximal Subungual Onychomycosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
Other Types
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

6. Global Onychomycosis Treatment Market By Geography, 2020-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2020 - 2033
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2033, (USD Mn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2033, (USD Mn)
U.K.
Germany
France
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2033, (USD Mn)
China
Japan
Australia
India
ASEAN
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2033, (USD Mn)
Mexico
Brazil
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2033, (USD Mn)
GCC
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2033, (USD Mn)
South Africa
Rest of Middle East, and Africa

7. Competitive Landscape

Lumenis Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Cipla Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Moberg Pharma AB
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Galderma SA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Dr. Reddys Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Medimetriks Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Analyst Views

8. Section

Research Methodology
About us